SCHEMBL3301602

SCHEMBL3301602

O=C(CCl)N1CCN(C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPX4 P36969 1/20 0.75
CACNA2D1 P54289 10/20 0.72
CACNB1 Q02641 10/20 0.72
CACNA1B Q00975 9/20 0.72
CACNA1C Q13936 7/20 0.72
CACNA1H O95180 1/20 0.72
ALDH1A1 P00352 2/20 0.71
USP2 O75604 1/20 0.67
MAPK1 P28482 1/20 0.67
CACNA1G O43497 2/20 0.66
NPC1 O15118 1/20 0.65
CACNA1A O00555 1/20 0.64
KMT2A Q03164 2/20 0.64
MAOB P27338 1/20 0.62
NPSR1 Q6W5P4 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MAPT P10636 1/20 0.60
HPGD P15428 1/20 0.60
PKM P14618 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160941 0.85 CACNA1G (0.69) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL5446443 0.84 GPX4 (0.76) GPX4CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4778556 0.84 CACNA2D1 (0.72) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
Z160 SCHEMBL4180792 0.84 CACNA2D1 (1.00) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL10076049 0.84 CACNA2D1 (0.72) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL917665 0.81 KMT2A (0.70) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL27545187 0.81 KMT2A (0.74) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL31350801 0.80 CACNA2D1 (0.67) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL5268519 0.80 CACNA2D1 (1.00) GPX4CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL5266301 0.80 CACNA2D1 (1.00) GPX4CACNA2D1CACNB1CACNA1BCACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US disclosed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US disclosed
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-09-03 US disclosed
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-09-03 US disclosed
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-09-03 US disclosed
WO-2007071035-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2007-06-28 WO disclosed
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels IONIX PHARMACEUTICALS LIMITED (GB) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels SCN1B, SCN1A, SCN10A GPX4 2069/4885CACNA2D1 105/4885CACNB1 23/4885
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS RYR2, CACNA1E, RYR1 GPX4 4354/4885CACNA2D1 45/4885CACNB1 18/4885
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1I, CACNA1C, ORAI1 GPX4 3478/4885CACNA2D1 44/4885CACNB1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.